Episode 12. ASH 2022 Myeloma Recap

1. GEM-CESAR and ASCENT Trials: Intensive Treatment Strategy in High-Risk Smoldering Multiple Myelomahttps://ash.confex.com/ash/2022/webprogram/Paper159606.htmlhttps://ash.confex.com/ash/2022/webprogram/Paper168930.html 2. What are the odds of having BMPC≥10% in a person with MGUS? IstopMM answers this question by developing a prediction model.https://ash.confex.com/ash/2022/webprogram/Paper170166.htmlLink to the model: https://istopmm.com/riskmodel/ 3. RCT comparing Rd (continuous) vs Rd induction-Mel140-AHCT-R Maintenance in transplant-eligible older adults (60-75 years) with newly diagnosed multiple myeloma https://ash.confex.com/ash/2022/webprogram/Paper159357.html 4. Talquetamab: Phase 1/2 results from Monumental-1https://tinyurl.com/kwn9en9mhttps://www.nejm.org/doi/full/10.1056/NEJMoa2204591 5. MALDI-TOF Mass Spect for Monoclonal Free Light Chain Assessment: A promising candidate for MRD testing in AL amyloidosishttps://tinyurl.com/yrvjjruv 6. Randomized Phase IV REAL Trial (VMP vs Rd) in New Diagnosed Transplant-Ineligible Myelomahttps://tinyurl.com/bde84xuw 7. Teclistamab-Daratumumab-Lenalidomide combination in earlier lines of therapy: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Studyhttps://ash.confex.com/ash/2022/webprogram/Paper159711.html 8. Three excellent abstracts from IstopMM:Is MGUS associated with autoimmune disease?https://tinyurl.com/5dafcz2wIs isolated hypercalcemia in a person with MGUS worrisome for transformation into myeloma?https://tinyurl.com/4tut3reaIs MGUS associated with CKD?https://tinyurl.com/34swvkj9 9. Outcome of patients with high-risk cytogenetic abnormalities in a secondary analysis of MASTER and Dara-VRD arm of GRIFFIN trialshttps://tinyurl.com/2n78yzfh 10. Surrogacy between PFS and OS in Multiple Myelomahttps://ash.confex.com/ash/2022/webprogram/Paper163855.htmlhttps://pubmed.ncbi.nlm.nih.gov/36495317/